CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $14.76M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 11.46: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
12.56BTWD393.47M · vs all stocks (USD)
Revenue (TTM)
471.13MTWD14.76M · vs all stocks (USD)
Profit Margin
4.78%52-Week Change
-1.72%vs all stocks
Market Capitalization
12.56BTWD393.47M · vs all stocks (USD)
Enterprise Value
11.53BTWD361.28M · vs all stocks (USD)
Forward P/E
-27.60xPrice to Sales (TTM)
26.48xPrice to Book (MRQ)
8.95xEnterprise to Revenue
24.47xEnterprise to EBITDA
-25.39xGross Margin
50.49%Profit Margin
4.78%Operating Margin
-58.18%Return on Assets (TTM)
-17.97%Return on Equity (TTM)
2.00%Revenue (TTM)
471.13MTWD14.76M · vs all stocks (USD)
Revenue per Share (TTM)
3.01TWDUpdated Aug 21, 2026Quarterly Revenue Growth
62.70%Gross Profit (TTM)
366.08MTWD11.47M · vs all stocks (USD)
EBITDA (TTM)
-454.14MTWD-14.23M · vs all stocks (USD)
Net Income (TTM)
22.50MTWD704.96K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-27.30%Operating Cash Flow (TTM)
-545.15MTWD-17.08M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
21.15MTWD662.63K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
431.27MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
137.06MTWDFY2025 · Dec 31, 2025Gross Profit
294.22MTWDFY2025 · Dec 31, 2025Operating Income
-862.32MTWD-27.02M · vs all stocks (USD)
Pre-tax Income
-858.20MTWDFY2025 · Dec 31, 2025Income Tax Expense
24.95MTWDFY2025 · Dec 31, 2025Net Income
-883.15MTWDFY2025 · Dec 31, 2025EBIT
-852.64MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-784.50MTWDFY2025 · Dec 31, 2025Research & Development
975.13MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
181.40MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
18.17MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.57MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-865.99MTWDFY2025 · Dec 31, 2025Free Cash Flow
-868.96MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
479.52MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-858.20MTWDFY2025 · Dec 31, 2025Stock-based Compensation
33.69MTWDFY2025 · Dec 31, 2025Other Non-cash Items
-12.61MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.67MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.21MTWDFY2025 · Dec 31, 2025Capital Expenditures
-2.96MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-12.54MTWDFY2025 · Dec 31, 2025Purchase of Investments
-220.70MTWDFY2025 · Dec 31, 2025Sale of Investments
75.00MTWDFY2025 · Dec 31, 2025Other Investing Activity
-547.00KTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
-149.21MTWDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00TWDFY2025 · Dec 31, 2025Long-term Debt Payments
-650.92MTWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
47.00MTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
-405.69MTWDFY2025 · Dec 31, 2025Shares Outstanding
157.54MSharesUpdated Aug 21, 2026Float Shares
99.76MSharesUpdated Aug 21, 2026% Held by Insiders
52.31%vs all stocks
% Held by Institutions
2.07%vs all stocks
Total Cash (MRQ)
910.92MTWD28.55M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.81TWDUpdated Aug 21, 2026Total Debt (MRQ)
30.55MTWD957.25K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0240xCurrent Ratio (MRQ)
8.98xBook Value per Share (MRQ)
8.85TWDUpdated Aug 21, 2026Total Assets
1.31BTWD41.06M · vs all stocks (USD)
Total Current Assets
985.71MTWDFY2025 · Dec 31, 2025Total Liabilities
380.78MTWDFY2025 · Dec 31, 2025Total Non-current Assets
324.68MTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
94.47MTWDFY2025 · Dec 31, 2025Total Current Liabilities
286.30MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
479.52MTWDFY2025 · Dec 31, 2025Other Short-term Investments
220.70MTWDFY2025 · Dec 31, 2025Accounts Receivable
43.48MTWDFY2025 · Dec 31, 2025Inventory
144.71MTWDFY2025 · Dec 31, 2025Accounts Payable
16.57MTWDFY2025 · Dec 31, 2025Short-term Debt
211.23MTWDFY2025 · Dec 31, 2025Other Current Liabilities
242.00KTWDFY2025 · Dec 31, 2025Long-term Debt
20.50MTWDFY2025 · Dec 31, 2025Common Stock (Book)
1.58BTWDFY2025 · Dec 31, 2025Retained Earnings
-6.69BTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
929.61MTWD29.13M · vs all stocks (USD)
52-Week Low
71.90TWDUpdated Aug 21, 202652-Week High
93.70TWDUpdated Aug 21, 202652-Week Change
-1.72%vs all stocks
50-Day MA
80.41TWDUpdated Aug 21, 2026200-Day MA
79.98TWDUpdated Aug 21, 2026Avg 10-Day Volume
89.44KSharesUpdated Aug 21, 2026Avg 30-Day Volume
116.53KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-1.22TWDUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 704,957.152Operating Cash Flow (USD, TTM): -17,083,460.313
High gross margins eroded by operating costsNotable
Gross Margin: 0.50Profit Margin: 0.05
Financial Health
Altman Z-Score 11.46: safe zoneNotable
Altman Z-Score: 11.46
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $14.76M, lower than 95% of all stocks globallySignificant
Revenue (USD): 14,763,675.963Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kontour Xi'an Medical Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule